Fragment-based Drug Discovery

InhibOx announces LOx - a new system for versatile fragment-based design

Submitted by InhibOx on 28 October 2010 - 9:30am

LOx offers a new pharmacophoric linking approach, integrated with Scopius, the largest available curated 3D compound and fragment database

Oxford, UK, October 28th, 2010. InhibOx Ltd today announces LOx 2.0 - a flexible new system to identify and optimize drug lead candidates through preserving and linking critical features with new scaffolds. Lox 2.0 carries fragment-linking tools a stage further and delivers a powerful approach for drug discovery scientists seeking to alter the core scaffold of a lead series to maximize activity, optimize physical properties and to create novel intellectual property.

AutoDock helps tackle two AIDS targets, HIV Protease and HIV Integrase

Submitted by InhibOx on 8 March 2010 - 7:29pm

Oxford, UK — 11th March, 2010.

The Scripps Research Institute and the FightAIDS@Home project announce new publications and the discovery of two new anti-HIV compounds.

A recent publication in the Journal of Molecular Biology, on which leading InhibOx scientist Dr. Garrett M. Morris is a co-author, describes a dynamic model of HIV integrase inhibition and drug resistance. This work employed the ligand-protein docking program, AutoDock, of which Garrett is a key developer.